The clinical utility index as a practical multiattribute approach to drug development decisions

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 1, 2009, Pages 105-108

  Poland, B ^a   Hodge, F L ^a   Khan, A ^b   Clemen, R T ^c   Wagner, J A ^b   Dykstra, K ^a   Krishna, R ^b  

^a PHARSIGHT CORPORATION   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS;

DECISION MAKING; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 67650596625     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.71     Document Type: Review

References (11)

1. Wallenius, J., Dyer, J.S., Fishburn, P.C., Steuer, R.E., Zionts, S. & Deb, K. Multiple criteria decision making, multiattribute utility theory: recent accomplishments and what lies ahead. Manage. Sci. 54, 1336-1349 (2008).
2. Keeney, R. & Raifa, H. Decisions With Multiple Objectives: Preferences and Value Tradeofs (Wiley, New York, 1976). Reprinted in 1993 by Cambridge University Press.
3. Korsan, B., Dykstra, K. & Pullman, W. Transparent trade-ofs: a clinical utility index (CUI) openly evaluates a product's attributes - and chance of success. Pharmaceutical Executive March (2005).
4. Dykstra, K.H., Hodge, F.L., Korsan, R. & Carrothers, T.J. Linking modeling & simulation, decision analysis, and the technology of drug formulation. American Conference on Pharmacometrics, Tucson, AZ, March 2008, Poster 67. .
5. Ouellet, D., Werth, J., Parekh, N., Feltner, N., McCarthy, B. & Lalonde, R.L. The use of a clinical utility index to compare insomnia compounds: a quantitative basis for beneft-risk assessment. Clin. Pharmacol. Ther. 85, 277-282 (2009).
6. Khan, A.A., Perlstein, I. & Krishna, R. The use of clinical utility assessments in early clinical development. AAPS J. 11, 33-38 (2009).
7. von Winterfeldt, D. & Edwards, W. Decision Analysis and Behavioral Research (Cambridge University Press, Cambridge, 1986).
8. von Neumann, J. & Morgenstern, O. Theory of Games and Economic Behavior (Princeton University Press, Princeton, NJ, 1944).
9. Orme, B.K. Getting Started With Conjoint Analysis: Strategies for Product Design and Pricing Research(Research Publishers LLC, Madison, WI, 2006).
10. Garrison, L.P. Jr., Towse, A. & Bresnahan, B.W. Assessing a structured, quantitative health outcomes approach to drug risk-beneft analysis. Health Af. (Millwood) 26, 684-695 (2007).
11. Hughes, D.A., Bayoumi, A.M. & Pirmohamed, M. Current assessment of risk-beneft by regulators: is it time to introduce decision analyses? Clin. Pharmacol. Ther. 82, 123-127 (2007).